Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 生物股份
Other Market Stock Code600201
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameCansinobio
Stock Code06185
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities研發、生產和商業化高質量、創新及經濟實惠的疫苗。公司正為12個疾病領域研發15種在研疫苗,涵蓋腦膜炎球菌疫苗、DTcP疫苗、肺炎球菌疫苗等,並已建成達國際標準的天津生產廠房。
Listing Date2019-03-28
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國天津市經濟技術開發區西區南大街185號西區生物醫藥園四層401-420
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitecansinotech.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 22.00 / shares
Offer Price RangeTo be extracted
Lot Size200 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2019-03-18 to 2019-03-21
Global Offering Shares57,248,600 shares
HK Public Offer Shares (Initial)5,725,200 shares (10.0%)
Public Offer Lots (Initial)28,626lots (Pool A14,313lots,Pool B14,313lots)
International Placing Shares (Initial)51,523,400 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO218,199,499 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share28.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,259,469,200

Stock Connect Inclusion Analysis

HK Market Cap HK$ 3.79B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣138.3百萬元
Period-End Cash Balance人民幣57.4百萬元
Listing Expenses~HK$ 107,300,000
Listing Expenses / Funds Raised~8.52%
Total Pre-IPO Investment人民幣743百萬元

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018
Revenue 001,132
Other income and gains, net 9,87320,99219,962
Administrative expenses -10,892-16,686-46,231
Operating profit -52,686-63,796-138,578
Net finance costs 2,835-654297
Profit before tax -49,851-64,450-138,281
Income tax expense 000
Profit for the year -49,851-64,450-138,281
Profit attributable to owners -49,851-64,450-138,281
Balance Sheet
Item 201620172018
Cash and cash equivalents 52,54818,24757,381
Inventories 01,6248,494
Total current assets 146,805426,918221,004
Total assets 326,173866,364795,875
Total current liabilities 27,356112,927106,685
Total liabilities 111,700259,032293,558
Total equity 214,473607,332502,317
Equity attributable to owners 214,473607,332502,317
Interest-bearing borrowings 69,329108,333150,000
Cash Flow Statement
Item 201620172018
Net cash from operating activities -34,383-56,301-123,638
Net cash from investing activities -173,543-461,490117,625
Net cash from financing activities 150,815484,37245,055
Net increase in cash -57,111-33,41939,042
Purchase of PP&E -126,080-164,469-149,423
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 34.7
First Day OpenHK$ 30.5
First Day Change57.73%
First Day Volume25930000.0
First Day Turnover820373000.0
Use of Proceeds
1、約80%(或920.7百萬港元)將用于我們核心產品以及我們疫苗產品線中其他主要產品的研發及商業化; 2、約10%(或115.1百萬港元)將用于臨床前在研疫苗的持續研發; 3、約10%(或115.1百萬港元)將用于營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (5)
Morgan Stanley Asia Limited CE AAD291 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894 ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 招银国际融资有限公司 CE AVM940
Joint Lead Managers (5)
Morgan Stanley Asia Limited CE AAD291 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 招银国际融资有限公司 CE AVM940

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 LAV Amber Limited 78,478,400 HKD — 6.23% — 6 months 2019-09-28
2 Worldwide Healthcare Trust PLC 196,200,400 HKD — 15.58% — 6 months 2019-09-28
3 津联卓睿投资有限公司 78,478,400 HKD — 6.23% — 6 months 2019-09-28

Directors & Management

PositionChinese nameEnglish Name
ChairmanXuefeng YU—
Company Secretary崔進、趙明璟—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東為Yu博士、朱博士、Qiu博士及Mao博士(根據一致行動人協議),緊隨全球發售完成後各自持有本公司總股本約31.71%、35.37%、31.71%及31.71%;LAV持有約15.47%。
About this page

This page shows Cansinobio (06185) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect